Immune activation is a major determinant for HIV-1 disease progression, and Toll-like receptor (TLR) ligands have been implicated in mediating HIV-1-associated immune activation [1, 2] . Plasmacytoid dendritic cells (pDCs) can play a central role in this HIV-1-induced activation of the immune system, as they can sense HIV-1 ssRNA via TLR7 and TLR8 [3, 4] and respond with interferon (IFN)-a production [5] . Genetic polymorphisms in TLR7, which is encoded on the X chromosome, have been associated with differential disease outcome in hepatitis C virus (HCV) and HIV-1 infections [6, 7] . Furthermore, IFN-a has been suggested to be a key mediator for simian immunodeficiency virus (SIV) pathogenesis in rhesus macaques [8, 9] , and pDCs from rhesus macaques, similar to humans, produce large amounts of IFN-a when stimulated with SIV or HIV-1. In contrast, sooty mangabeys, the natural host of SIV that do not progress to AIDS [10] , have significantly lower levels of T-cell activation in chronic SIV infection and have been reported to have lower IFN-a levels in chronic SIV infections [8, 11, 12] . Here, we examined the consequences of polymorphisms in TLR7 and key signaling molecules in the TLR7 pathway, such as MyD88 and interferon regulatory factor 7 (IRF7), on IFN-a production following stimulation with HIV-1.
Blood specimens from 35 healthy donors were drawn in acid citrate dextrose tubes. Freshly isolated peripheral blood mononuclear cells were stimulated with 0.3 mg/ml p24 of aldrithiol-2 (AT-2) inactivated HIV-1 (Lot# P4092) or equivalent amount of microvesicle control (Lot# P4138) as previously described [5] . After 20 h, cells were washed and stained for phenotypical surface markers as well as intracellular cytokine production. To identify genetic polymorphisms, the entire gene coding regions of TLR7, MyD88, and IRF7 genes were amplified from genomic DNA in 10 ml reactions containing 200 nm deoxyribonucleotide triphosphates, 1.5 mmol/l MgCl 2 , and 0.2 mmol/l of each primer. A modified step-down program was used to ensure precise amplification. PCR products were subjected to direct bidirectional cycle sequencing using Bigdye terminator, version 1.1, and run on an ABI3730 sequencer (Applied Biosystems, Foster City, California). Unpaired two-tailed Student's t-tests were employed to assess statistical significance of differences. P values of less than 0.05 were considered statistically significant.
Within TLR7, two single nucleotide polymorphism (SNPs), rs179008 and rs2302267 located on the X chromosome, have been previously described to be associated with various HCV and HIV-1 disease outcomes [6, 7] . In this cohort, individuals with G (as opposed to T) in SNP rs2302267 were rare (n ¼ 2) and, therefore, an accurate analysis of the functional consequences of this SNP could not be performed. Four individuals who were heterozygous (AT) and nine individuals who were homozygous or hemizygous (TT or T) for the TLR7 SNP rs179008 at position exon 3 were identified. However, the percentage of pDCs that produced IFN-a in response to AT-2 HIV-1 stimulation was not significantly different between the study groups [median %IFN-aþ pDCs: AA (women) or A (men) 6.57%; AT 5.38%; TT or T 5.46%; P > 0.05]. This is in contrast to previously published work reporting that stimulation with the TLR7/8 ligand imiquimod resulted in higher amounts of secreted IFN-a by individuals with the rarer polymorphism (TT or T) [7] . This discrepancy might be due to difference in the stimulants used (synthetic TLR ligands versus ssRNA and inactivated HIV-1 virus here) and measuring IFN-a by secretion rather than by percentage of IFN-aþ pDCs.
Downstream of TLR7 a cascade of signaling molecules is activated before the transcription of IFN-a One of the first proteins that TLR7 and almost all other TLRs interact with is MyD88. We found no genetic polymorphisms within MyD88 in the 35 individuals studied here. IFN-a transcription is furthermore dependent on IRF7 and a total of 10 described IRF7 SNPs were characterized in the study participants. Two SNPs, rs12272434 and rs12290989, both located at intron/exon boundaries, were associated significantly with decreased levels of IFN-a production by pDCs in response to HIV-1 (Fig. 1a ). The two SNPs were in complete linkage disequilibrium, so only SNP rs12272434 is used as representative of both SNPs in all subsequent analyses. The decreased capacity to produce IFN-a was most prominent in the seven individuals who were homozygous for the rarer polymorphism (AA) and to a lesser degree in individuals who were heterozygous. IFN-a is a pro-inflammatory cytokine that can directly activate T cells. Consequently, the difference in IFN-a production was also reflected by significant differences in the level of CD8 þ T-cell activation, with individuals who were heterozygous (AT) or homozygous (AA) for the rs12272434 and rs12290989 SNPs having a significantly lower level of activated T cells ( Fig. 1b ). Both IFN-a and T-cell activation associations were, however, not sex-specific and the same pattern was observed in both men and women (data not shown). For the remaining eight IRF7 SNPs, we either did not identify significant association with differences in IFN-a production (226_231 intron deletion, rs1061502, rs11246213, rs10902178) or did not have a sufficient number of individuals with the rarer polymorphisms for accurate analysis (rs1061505, rs1131665, rs12422022, rs1051390).
HIV-1 infection is associated with strong activation of the immune system, and the level of immune activation is a strong predictor for HIV-1 disease progression [13] . Levels of HIV-1-associated immune activation for the same level of viral replication can vary largely between individuals, and the mechanisms underlying these differences are incompletely understood. In this study, two IRF7 SNPs were identified to have a significant impact on IFN-a production by pDCs following stimulation with AT-2 inactivated HIV-1. IRF7 binding to the IFN-a promoter requires protein phosphorylation, formation of homodimers, and transport to the nucleus [14] . Whether the studied polymorphisms in IRF7 affect transcription of the gene, phosphorylation of the protein, or binding to the IFN-a promoter needs to be further examined to determine the mechanism behind the observed differences in IFN-a production.
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The authors thank the Brigham and Women's Hospital PhenoGenetic Project for providing DNA samples from healthy individuals that were used in the replication effort of this study. These studies were supported by RO1 216753 and the Doris Duke Charitable Foundation. They also thank the Phillip T. and Susan M. Ragon Fig. 1 . Differential Toll-like receptor 7 responses associated with interferon regulatory factor 7 polymorphism. (a) Peripheral blood mononuclear cells from healthy donors were stimulated with aldrithiol-2 (AT-2) inactivated HIV-1 or microvesicle (Ves) control, and the percentage of plasmacytoid dendritic cells (pDCs) producing interferon-a (IFN-a) was determined by intracellular cytokine staining. Individuals with the most common polymorphism in the interferon regulatory factor 7 (IRF7) single nucleotide polymorphism (SNP) rs12272434 (TT; n ¼ 21) and those who were heterozygous for this SNP (AT; n ¼ 7) had significantly higher levels of IFN-a production compared to those who were homozygous for the less common polymorphism (AA; n ¼ 7). (b) CD8 þ Tcell activation levels as measured by high expression of CD38 were quantified in a subset of individuals for which sufficient cell numbers were available (TT; n ¼ 16, AT; n ¼ 7, and AA; n ¼ 7). HIV-1-induced CD8 þ T-cell activation was significantly higher in individuals with TT. Pneumonia burden is substantially higher in HIVinfected compared with HIV-uninfected children [1] [2] [3] [4] . Following the 1996 introduction of highly active antiretroviral therapy (HAART), the incidence of bacterial pneumonia in HIV-infected children in the US declined several-fold [4] . Since 2000, widespread heptavalent conjugate pneumococcal (PCV7) vaccination has decreased the incidence of invasive pneumococcal disease in the general pediatric population [5] [6] [7] [8] [9] [10] [11] [12] . However, the incidence of community-acquired pneumonia (CAP) in HIV-infected children following PCV7 licensure is unknown.
This retrospective cohort study between 1 January 2000 and 31 December 2005 used the US multicenter HIV Research Network (HIVRN). Eligible participants were HIV-infected, 21 years of age or less, and followed longitudinally. CAP was defined as clinician-diagnosed pneumonia in a patient initially evaluated in a primary care setting. Cases of Pneumocystis jiroveci pneumonia (PCP) were excluded. Change in CAP annual incidence was evaluated using x 2 test for trend. Patients were matched on age category and year to account for known CAP risk factors [12] and to control for temporal factors such as changes in CAP incidence or influenza seasonal severity. Risk factor analysis using a 3 : 1 match for controls : cases explored associations between patient characteristics and CAP using bivariate and multivariate logistic regression, clustering by site of care. Variables with P < 0.2 were included in the multivariate model and the most parsimonious multivariate model was identified. Pneumococcal vaccination data from two sites were available for a sub-analysis. Vaccination status was defined as: 'any vaccine', at least one dose of either PCV7 or 23-valent pneumococcal polysaccharide vaccine (PS23); 'vaccinated with PCV7', at least two doses of PCV7; and 'vaccinated with PS23', at least one dose of PS23 in the 5 years preceding a CAP episode. Institutional review board approval was obtained at all sites.
From 2000 to 2005, 736 children were enrolled in the HIVRN and followed for 2675 person-years. Characteristics at enrollment are summarized ( Table 1 ). There were 87 CAP episodes; an incidence of 33. In matched comparison of cases and controls, the mean CD4 percentage was 23% and 30%, and the median CD4 cell count was 668 and 870 cells/ml, respectively. In unadjusted bivariate analysis, a viral load at least 100 000 copies/ml and a CD4 percentage below 15% ( A temporal decrease in incidence of CAP occurred from 2000 to 2005 in HIV-infected children and adolescents in the USA. The degree to which this decline was attributable to conjugate pneumococcal vaccine or HAART-derived immune benefits is unknown. However, analysis of a subset of the cohort did not support a protective effect of pneumococcal vaccination.
The finding that the incidence of CAP in HIV-infected children has decreased is important. A crucial next step is to ascertain whether the incidence of CAP in this group is approaching that in the general pediatric population. If not, the reasons for this, such as an suboptimal vaccination response, will need to be established to inform future intervention strategies.
Our findings on univariate analysis that a viral load at least 100 000 copies/ml and CD4 percentage below 15% are associated with CAP are consistent with previous studies [4, 13] . These highlight the importance of ensuring sustained, rather than just initial, viral load control and CD4 percentage response following HAART. On multivariate analysis, only viral load at least 100 000 copies/ml was associated with CAP.
The lack of association between inadequate vaccination and CAP is surprising. Widespread PCV7 immunization in the USA has resulted in herd immunity [13] which may have diluted the effect of vaccination in this study. In addition, this suggests that HAART-derived immune reconstitution may be a more important protective factor against CAP, though this finding requires confirmation in larger studies.
In our study, CAP incidence was similar in those prescribed PCP prophylaxis compared to those not. Studies examining the effects of trimethoprim-sulfamethoxazole on the risk of bacterial infections have demonstrated varied results [14, 15] . We speculate that, although PCP prophylaxis likely provides some level of protection against CAP of bacterial cause, it has no effect against CAP of viral cause.
Study limitations included the unknown vaccine status of the whole cohort and the potential that CAP diagnosis could be subject to misclassification. Such misclassification is, however, unlikely because clinicians used a consistent definition of CAP. In addition, any misclassification should not differ between 2000-2001 and 2002-2005. A temporal decrease in incidence of CAP occurred from 2000 to 2005 in HIV-infected children and adolescents.
Ongoing monitoring of CAP in HIV-infected children must remain an important priority until their risk is no greater than that seen in their HIV-uninfected peers.
Herd immunity through pneumococcal immunization may have diluted the effect of individual immunization in this cohort.
